Fig. 8: Schematic of CI-HS and CC-HS-treated CFH(Y/Y)-iRPE and CFH(H/H)-iRPE.
From: Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model
a–d Schematic of CFH(Y/Y)-RPE (a, c) and CFH(H/H)-iRPE (b, d) following CI-HS (a, b) or CC-HS (c, d) treatments. Under basal (CI-HS) conditions, CFH(H/H)-iRPE show higher tendency for sub-RPE deposits as compared to CFH(Y/Y)-iRPE, likely because of increased alternate complement activation around RPE cells (a, b). Enhanced activation of human complement (CC-HS) further exaggerates AMD cellular phenotypes in iRPE cells; CFH(H/H)-iRPE show predisposition to disease as compared to CFH(Y/Y)-iRPE (c, d).
